MAP2K1 and melanoma: The NRAS Q61K mutation is also an oncogenic hotspot (COSM580), and there is promising clinical data in patients with oncogenic NRAS‐mutant melanoma treated with the MEK1/2‐inhibitor, binimetinib (Dummer et al., 2017).